Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor

Xue, Rui; Jin, Zeng-liang; Chen, Hongxia; Li, Yuan; He, Xinhua; Zhang, Yanping; Meng, Yonggang; Xu, Jiang; Zheng, Jimin; Zhong, Benhe; Li, Yunfeng; You-zhi, Zhang

doi:10.1016/j.euroneuro.2012.06.001

Cited by 48 publications

(56 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ammoxetine is the S-(-) isomer of 071031B ((±)-3-(benzo[d] [1,3]dioxol-4-yloxy)-N-methyl-3-(thiophen-2-yl)propan-1-amine) and was described as a novel 5-HT and NE reuptake inhibitor [25][26][27] . Our unpublished data proved that ammoxetine is a potent and selective SNRI with weak affinity to the DA (dopamine) transporter, monoamine oxidase, histamine, cholinergic, and 16 other GPCR opioid receptors.…”

Section: Original Articlementioning

confidence: 99%

Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor

Zhang

Xue²,

Zhu

et al. 2016

Acta Pharmacol Sin

Self Cite

View full text Add to dashboard Cite

Aim:The selective serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors (SNRIs) are commonly used for the treatment of neuropathic pain and fibromyalgia. Ammoxetine ((±)-3-(benzo [d] [1,3]dioxol-4-yloxy)-N-methyl-3-(thiophen-2-yl)propan-1-amine) has been identified as a novel potent SNRI. In this study, we evaluated the acute analgesic properties of ammoxetine in different animal models of pain, and examined the involvement of monoamines in its analgesic actions. Methods: The analgesic effects of ammoxetine were assayed using models of acetic acid-and formalin-induced pain in mice, neuropathic pain induced by sciatic nerve injury (SNI), chronic constriction injury (CCI) and reserpine-induced fibromyalgia pain in rats. The contents of 5-HT and NE in brain regions of fibromyalgia rats were measured using HPLC-ECD. In all the experiments, duloxetine was used as a positive control drug. Results: Oral administration of ammoxetine (0.625-10 mg/kg) or duloxetine (2.5-40 mg/kg) dose-dependently decreased the number of acetic acid-induced writhing and formalin-induced first phase and second phase paw licking time in mice. Oral administration of ammoxetine (2.5-10 mg/kg) or duloxetine (10 mg/kg) alleviated mechanical allodynia in SNI and CCI rats and thermal hyperalgesia in CCI rats. The antiallodynic effect of ammoxetine in CCI rats was abolished by pretreatment with para-chlorophenylalanine methyl ester hydrochloride (PCPA, a 5-HT synthesis inhibitor) or α-methyl-para-tyrosine methylester (AMPT, a catecholamine synthesis inhibitor). Oral administration of ammoxetine (30 mg/kg) or duloxetine (50 mg/kg) significantly attenuated tactile allodynia in rats with reserpine-induced fibromyalgia. In the fibromyalgia rats, administration of ammoxetine (10, 30 mg/kg) or duloxetine (30, 50 mg/kg) dose-dependently increased the levels of 5-HT and NE, and decreased the metabolite ratio of 5-HT (5-HIAA/5-HT) in the spinal cord, hypothalamus, thalamus and prefrontal cortex. Conclusion: Ammoxetine effectively alleviates inflammatory, continuous, neuropathic and fibromyalgia-related pain in animal models, which can be attributed to enhanced neurotransmission of 5-HT and NE in the descending inhibitory systems.

show abstract

Section: Original Articlementioning

confidence: 99%

Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor

Zhang

Xue²,

Zhu

et al. 2016

Acta Pharmacol Sin

Self Cite

View full text Add to dashboard Cite

show abstract

“…Depression affects an estimate of 350 million individuals worldwide (1) and is a serious public health problem due to its high morbidity, recurrence and suicide rate (2). Decades of extensive study of the pathophysiology of depression have led to various hypotheses regarding its molecular basis.…”

Section: Introductionmentioning

confidence: 99%

Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress

Gao

Zhu

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Atractylenolide I (AT-I), a major component of the rhizoma of Atractylodes macrocephala Koidz., exerts a wide range of activities. The purpose of the present study was to investigate the anti-depressant-like effect of AT-I in a mouse model of chronic unpredictable mild stress (CUMS), and to explore the possible molecular mechanism involved. It was revealed that AT-I significantly ameliorated CUMS-induced depressive-like behaviors, as evidenced by increased sucrose preference as well as shortened immobility time in the forced swimming and the tail suspension test. In addition, AT-I reduced CUMS-induced decreases in the concentrations of serotonin and norepinephrine in the hippocampus. Furthermore, AT-I inhibited the activation of the nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome as well as the concentration of the pro-inflammatory cytokine interleukin (IL)-1β in the hippocampi of mice subjected to CUMS. In conclusion, the results of the present study suggested that AT-I exerts anti-depressant-like effects in a CUMS-induced model of depression in mice, the molecular mechanism of which is associated with the inhibition of NLRP3 inflammasome activation to decrease IL-1β production.

show abstract

“…Depression is a chronic mental disease that affects more than 10% of population [36] and has become one of the most prevalent public health problems because of high rate of morbidity, recurrence, and mortality [37]. Depression is more common in females than males [38] and the women tend to have more depressive symptoms, during the times of large hormonal changes, suggesting that the hormonal changes plays a key role in the pathogenesis of depression [39,40].…”

Section: Discussionmentioning

confidence: 99%

Influence of Gender Difference in the Antidepressant Effect of Fluoxetine in Mice in Tail Suspension Test

Tyagi¹,

Walia

2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Aim:To determine the effect of gender difference in the antidepressant effect of fluoxetine (FLX) in mice in tail suspension test (TST).Methods: Swiss albino mice of either sex were used and the depression-like behavior was measured by TST.Results: The present study showed that there was a significant difference in the immobility period of male mice and female mice in TST. However, the antidepressant effect of FLX differs significantly in male mice and female mice in TST. Conclusion:It has been concluded that the antidepressant effect of FLX in TST was affected by the gender difference as suggested by the results of the present study.

show abstract

Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor

Cited by 48 publications

References 48 publications

Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor

Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor

Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress

Influence of Gender Difference in the Antidepressant Effect of Fluoxetine in Mice in Tail Suspension Test

Contact Info

Product

Resources

About